923032-78-4Relevant academic research and scientific papers
BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS
-
, (2014/01/07)
This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administred to a Hepatocellu
N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK
-
Page/Page column 79, (2008/06/13)
This invention concerns N-(2-arylamino) aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.
